Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

GLP-1 drugs such as Ozempic and Mounjaro have been heralded as some of the most important drug breakthroughs ever . This has ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...